Search results
Author(s):
Markus Flesch
Added:
3 years ago
Introduction
Chronic heart failure (HF) is a common, malignant disease and is a major economic burden for healthcare systems in developed nations. It affects 5% to 10% of all people. In Germany, approximately 150,000 people are newly diagnosed with HF per year. Fifteen per cent of approximately 1.6 million HF patients in Germany are in advanced HF status, being classified as stage III-IV…
View more
Author(s):
Giuseppe Rosano
,
Harriette Van Spall
Added:
5 months ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Phosphodiesterase-5 Inhibition in Chronic Heart Failure - An Emerging Therapeutic Opportunity
Author(s):
Marco Guazzi
Added:
3 years ago
Article
Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure
Author(s):
Moritake Iguchi
,
Shuichi Ura
,
Nobutoyo Masunaga
,
et al
Added:
3 years ago
Article
Author(s):
Serge Masson
,
Roberto Latini
Added:
3 years ago
Chronic heart failure (HF) is a major cause of death and disability. Predicting patients at risk of death or further cardiovascular events that require more intense monitoring and therapy is clinically challenging. Several factors are associated with increased mortality and morbidity in patients with HF, including age, a history of diabetes mellitus or renal dysfunction, advanced functional…
View more
Author(s):
Roland Wensel
,
Michael Arzt
,
Sylvia Montalvan-Dobmayr
,
et al
Added:
3 years ago
Periodic Breathing - Central Sleep Apnoea (CSA)
CSA is a periodic waxing and waning of ventilation. In chronic heart failure (CHF), CSA is a result of increased chemoreflex sensitivity, prolonged circulation time (low cardiac output) and low functional residual capacity (Francis et al. Circulation 2000).
In CHF, CSA is associated with advanced disease and poor prognosis (Lafranchi et al…
View more
Author(s):
R Sane
Added:
3 years ago
Aim: Chronic heart failure (CHF) is a common cause of mortality and morbidity. Obesity influences the CHF development and prognosis. This study was conducted to assess effect of heart failure reversal therapy (HFRT), a combination of panchakarma and allied therapies, on anthropometric parameters in CHF patients.
Methods: This retrospective study was conducted on data of patients who visited…
View more
Author(s):
R Sane
Added:
3 years ago
Aims: New treatment modalities are needed to improve the aerobic capacity of patients with chronic heart failure (CHF), considering the increasing disease prevalence. This study was done to evaluate the effect of heart failure reversal therapy (HFRT) on exercise indices, viz.VO2 max and metabolic equivalents (METs).
Methodology: This retrospective study screened data of 147 patients who visited…
View more
Author(s):
Christoph Maack
,
Michael Böhm
Added:
3 years ago
Chronic heart failure is the leading cause of hospitalisation in Germany1 and other European countries. It is the result of various cardiovascular diseases, such as myocardial infarction, arterial hypertension and valvular heart diseases. About 50 % of patients with heart failure have normal systolic, but impaired diastolic function, a condition termed heart failure with preserved ejection…
View more
Author(s):
Marco Metra
,
Savina Nodari
,
Livio Dei Cas
Added:
3 years ago
Beta-blocker therapy remains one of the most fascinating issues in heart failure (HF) clinical practice. These agents, once absolutely contraindicated in patients with HF, have been shown to have the greatest beneficial effects on the patients' prognosis. They have radically changed the clinical course of HF, more than any other agent previously introduced, and are now the cornerstone of current…
View more